Careers article - October 12, 2020
Recruitment drive underway at Diamyd Medical
The company is moving its production of the GAD65 protein, the active substance in its diabetes vaccine Diamyd, from abroad to Umeå, Sweden. The new unit is around 1,000 square meters in size and contains clean rooms, laboratories and offices. Today, the unit has six employees, including protein scientists and quality management. ”We are short […]
Clinical Trials - April 4, 2016
Diamyd’s study approved for expansion
Diamyd Medical today announced that DIAGNODE-1, an open-label clinical pilot study in which the diabetes vaccine Diamyd is administered directly into lymph nodes, has been approved by the Swedish Medical Products Agency and the Ethics Review Board to be expanded from five to nine patients and to include children from 12 years of age. Professor […]
MedTech Business - February 29, 2016
Diamyd Medical’s rights issue oversubscribed
Diamyd Medical has completed a new share issue with preferential rights for existing shareholders through which the company will receive proceeds of MSEK 22.1 before issue expenses. There has been substantial interest in the issue. Subscription applications totaling approximately MSEK 45.8 were received, corresponding to a subscription rate of about 207 percent. 94.6 percent of the […]
Clinical Trials - February 20, 2016
Preliminary interim report from Diamyd’s DIAGNODE-1
Diamyd Medical announces that the first six-month interim report from DIAGNODE-1, a clinical pilot study in which the diabetes vaccine Diamyd is administered directly into lymph nodes, preliminarily shows that the treatment appears to be safe and tolerable and that the clinical progression in patients is positive in terms of the body’s own capacity to […]
Uncategorized - August 1, 2015
Cellaviva launches new service
Diamyd Medical’s associated company Cellaviva launches service for private family saving of stem cells. Diamyd Medical has announced that the their associated company Cellaviva AB on September 1 launches its service in which expecting parents in Sweden can save stem cells from their newborn child. Stem cells from the baby’s umbilical cord are saved and stored […]
Collaboration - May 11, 2015
Biobank Could Help Diamyd with Diabetes Vaccine
Diamyd, which is developing a vaccine against type 1 diabetes, now owns 39 percent of Cellaviva, Sweden’s first commercial biobank for stem cells. Diamyd made the investment because of the potential resource for research. “We believe in stem cells. Among other things, we hope that in the future we will be able to use them […]